[
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Stock Moves -0.25%: What You Should Know",
    "summary": "In the latest trading session, Johnson & Johnson (JNJ) closed at $149.23, marking a -0.25% move from the previous day.",
    "url": "https://finnhub.io/api/news?id=db7156f0266a376dd42eb0cb7061fb48c9427a84b29346715eeb403da177067a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733870710,
      "headline": "Johnson & Johnson (JNJ) Stock Moves -0.25%: What You Should Know",
      "id": 131917533,
      "image": "https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "In the latest trading session, Johnson & Johnson (JNJ) closed at $149.23, marking a -0.25% move from the previous day.",
      "url": "https://finnhub.io/api/news?id=db7156f0266a376dd42eb0cb7061fb48c9427a84b29346715eeb403da177067a"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson stock underperforms Tuesday when compared to competitors",
    "summary": "Johnson & Johnson stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=b59b8d2ab90d21198bb67000b0da9f5b4e904aad80d245c3d02e74d60a52aefd",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733848260,
      "headline": "Johnson & Johnson stock underperforms Tuesday when compared to competitors",
      "id": 131933286,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=b59b8d2ab90d21198bb67000b0da9f5b4e904aad80d245c3d02e74d60a52aefd"
    }
  },
  {
    "ts": null,
    "headline": "Retired Investor Living Off $160,000 In Dividends Shares Stock Portfolio – 'We Live Quite Comfortably On Dividends'",
    "summary": "Investing in dividend stocks is an effective strategy for securing a reliable income stream during retirement. A study from Ned Davis Research showed that dividend stocks returned about 8.8% annually in aggregate between 1972 and 2012, compared with ...",
    "url": "https://finnhub.io/api/news?id=f0c3047a1fb185fd1641702a9043c11c1ecade9ac434e2e6b54b94872caac80e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733848063,
      "headline": "Retired Investor Living Off $160,000 In Dividends Shares Stock Portfolio – 'We Live Quite Comfortably On Dividends'",
      "id": 131905019,
      "image": "https://media.zenfs.com/en/benzinga_79/58d4aafac51310a5d9d66fce9ca15c6e",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Investing in dividend stocks is an effective strategy for securing a reliable income stream during retirement. A study from Ned Davis Research showed that dividend stocks returned about 8.8% annually in aggregate between 1972 and 2012, compared with ...",
      "url": "https://finnhub.io/api/news?id=f0c3047a1fb185fd1641702a9043c11c1ecade9ac434e2e6b54b94872caac80e"
    }
  },
  {
    "ts": null,
    "headline": "Buy 1 December Aristocrat Of 67 From 38 With 'Safer' Dividends",
    "summary": "67 Aristocrats span all sectors, with BEN topping yields. Read why its strong dividend history and low price make it a December buy, despite analyst concerns.",
    "url": "https://finnhub.io/api/news?id=b7d91ae2ae781cb668d998e7e5af207aba8601a46994e0e31da4474ab4afa404",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733845375,
      "headline": "Buy 1 December Aristocrat Of 67 From 38 With 'Safer' Dividends",
      "id": 131907202,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1157043971/image_1157043971.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "67 Aristocrats span all sectors, with BEN topping yields. Read why its strong dividend history and low price make it a December buy, despite analyst concerns.",
      "url": "https://finnhub.io/api/news?id=b7d91ae2ae781cb668d998e7e5af207aba8601a46994e0e31da4474ab4afa404"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results",
    "summary": "NEW BRUNSWICK, N.J., December 10, 2024--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Wednesday, January 22nd to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s",
    "url": "https://finnhub.io/api/news?id=6f958219ee8d3f2a4a6c4808ae2c35b8321bacc51cc26187349b66a6f6420a03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733835600,
      "headline": "Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results",
      "id": 131903486,
      "image": "https://s.yimg.com/ny/api/res/1.2/425jUPqjQfzE4lHbUgUVvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xMTI-/https://media.zenfs.com/en/business-wire.com/813b6549f67a25c1c7a3a0303b4461ac",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "NEW BRUNSWICK, N.J., December 10, 2024--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Wednesday, January 22nd to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s",
      "url": "https://finnhub.io/api/news?id=6f958219ee8d3f2a4a6c4808ae2c35b8321bacc51cc26187349b66a6f6420a03"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson : 2024 Fourth-Quarter Press Release & Supplemental Schedules",
    "summary": "Media contact: Investor contact: ...",
    "url": "https://finnhub.io/api/news?id=fc23110e97bd4119a5671eebaf937921d839e8d6671cb41ee14eb0b30f710571",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733833014,
      "headline": "Johnson & Johnson : 2024 Fourth-Quarter Press Release & Supplemental Schedules",
      "id": 131904656,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Media contact: Investor contact: ...",
      "url": "https://finnhub.io/api/news?id=fc23110e97bd4119a5671eebaf937921d839e8d6671cb41ee14eb0b30f710571"
    }
  },
  {
    "ts": null,
    "headline": "IGD Continues To Show Improvements, Now Covering Distribution",
    "summary": "Voya Global Equity Dividend and Premium Opportunity Fund offers a high 10.70% yield, higher than most of its peers. Find out my recommendation for IGD.",
    "url": "https://finnhub.io/api/news?id=5b7fd69f4bbfaff38f7d4e61d556a8a153124983bf45ed294724a3c30f5b584c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733806621,
      "headline": "IGD Continues To Show Improvements, Now Covering Distribution",
      "id": 131899192,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/88621226/image_88621226.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Voya Global Equity Dividend and Premium Opportunity Fund offers a high 10.70% yield, higher than most of its peers. Find out my recommendation for IGD.",
      "url": "https://finnhub.io/api/news?id=5b7fd69f4bbfaff38f7d4e61d556a8a153124983bf45ed294724a3c30f5b584c"
    }
  },
  {
    "ts": null,
    "headline": "Market Leadership Is Narrow. Your Portfolio Shouldn't Be",
    "summary": "2024 S&P 500 Index performance has been among some of the strongest in history, adding to similarly strong performance in recent years.",
    "url": "https://finnhub.io/api/news?id=bfd2bc7d49a8be9e8448b2e327b0cec4e3ca01f178482b9dbb6cfe300de4b04a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733798400,
      "headline": "Market Leadership Is Narrow. Your Portfolio Shouldn't Be",
      "id": 131898207,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1477909330/image_1477909330.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "2024 S&P 500 Index performance has been among some of the strongest in history, adding to similarly strong performance in recent years.",
      "url": "https://finnhub.io/api/news?id=bfd2bc7d49a8be9e8448b2e327b0cec4e3ca01f178482b9dbb6cfe300de4b04a"
    }
  },
  {
    "ts": null,
    "headline": "CARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study",
    "summary": "Johnson & Johnson (NYSE:JNJ) announced today new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) significantly increased minimal residual disease (MRD) negativity rates (10-5) in patients with relapsed or refractory multiple myeloma (RRMM) who were lenalidomide-refractory and had received one to three prior lines of therapy, including a proteasome inhibitor (PI), compared to standard therapies of pomalidomide, bortezomib",
    "url": "https://finnhub.io/api/news?id=8bcb6270f0ba43e7854161b9128c02c7d2547fb7b6a04c7a608f957ebbde401a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733790600,
      "headline": "CARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study",
      "id": 131897709,
      "image": "https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) announced today new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) significantly increased minimal residual disease (MRD) negativity rates (10-5) in patients with relapsed or refractory multiple myeloma (RRMM) who were lenalidomide-refractory and had received one to three prior lines of therapy, including a proteasome inhibitor (PI), compared to standard therapies of pomalidomide, bortezomib",
      "url": "https://finnhub.io/api/news?id=8bcb6270f0ba43e7854161b9128c02c7d2547fb7b6a04c7a608f957ebbde401a"
    }
  }
]